Strongyloides stercoralis is a soil-transmitted helminth that infects an estimated 300 to 600 million people worldwide, yet it remains notoriously difficult to diagnose because the parasite persists at low levels in the intestine and sheds larvae intermittently. What makes the infection clinically dangerous is its unique ability to complete its life cycle entirely within the human host through autoinfection, allowing the worm to survive for decades. In individuals whose immunity becomes suppressed, for example by corticosteroid therapy or other conditions, the parasite can multiply uncontrollably and cause hyperinfection syndrome, a frequently fatal complication. Understanding the immune landscape of chronic infection is therefore not merely an academic exercise; it is central to identifying who is at risk and how the disease can be detected earlier.

The research team enrolled 82 individuals with confirmed S. stercoralis infection and 48 uninfected controls living in the same endemic region of Khuzestan province, a design that allowed them to distinguish infection-specific immune changes from background environmental exposures common to both groups. All infected participants presented with eosinophilia, an elevated count of eosinophils, the white blood cells classically associated with defense against parasitic worms. To probe the immune response, the investigators developed in-house enzyme-linked immunosorbent assays to measure antibodies directed against Strongyloides antigens, together with bead-based multiplex assays capable of quantifying a broad panel of cytokines and chemokines in serum.

The antibody results were striking in their subclass specificity. Infected individuals showed significantly elevated Strongyloides-specific immunoglobulin G responses compared with endemic healthy controls, but this elevation was not uniform across all IgG classes. Instead, IgG4 and IgG1 emerged as the dominant subclasses, while IgG2 responses were minimal. This pattern is immunologically meaningful: IgG4 is the subclass most consistently induced by chronic helminth exposure and is often interpreted as a marker of prolonged, repeated antigenic stimulation under a regulatory immune environment. The prominence of IgG1 alongside it suggests a robust, active antibody response to the parasite rather than a purely dampened one, painting a picture of coexisting activation and regulation that is characteristic of long-term worm carriage.

The cytokine data reinforced this type 2 orientation. Infected participants displayed significantly increased serum concentrations of interleukin-4, interleukin-5, interleukin-13, and interleukin-9, the canonical cytokines produced by type 2 helper T cells and, in the case of IL-9, by the increasingly recognized type 9 lineage. IL-4 drives class switching toward IgG4 and IgE, IL-5 recruits and activates eosinophils, and IL-13 promotes mucus production and tissue remodeling at mucosal barriers, all mechanisms directly relevant to expelling intestinal worms. The elevation of IL-9 adds an interesting dimension, as this cytokine has been implicated in mast cell responses and barrier immunity, processes thought to contribute to controlling helminth establishment in the gut.

Perhaps the most unexpected finding concerned the chemokine CXCL9, an interferon-inducible chemokine typically associated with type 1 inflammatory responses and the recruitment of T cells and natural killer cells. The researchers recorded a striking increase in CXCL9 among infected subjects, standing in apparent contrast to the dominant type 2 profile. Meanwhile, the majority of Th1- and Th17-associated cytokines, along with several pro-inflammatory chemokines, were either reduced during infection or increased after treatment and parasite clearance. This suggests that S. stercoralis actively suppresses inflammatory pathways while leaving, or even provoking, a specific interferon-driven chemokine signal, a combination that may reflect the parasite’s strategy of securing long-term survival while the host retains enough immune pressure to keep worm numbers in check.

A longitudinal component of the study strengthened the causal interpretation of these immune signatures. Eighteen patients were reassessed at least six months after receiving albendazole, one of the standard anthelmintic drugs used against strongyloidiasis. Following treatment and presumed parasite clearance, the researchers documented significant reductions in eosinophil counts, parasite-specific IgG1, IgG2, and IgG4 levels, and serum concentrations of both IL-9 and IL-10, the latter being an immunoregulatory cytokine often elevated during chronic helminth infection. In contrast, systemic IL-4 concentrations increased after therapy, an intriguing reversal that the authors note alongside the broader normalization of the infection-associated immune profile. The parallel decline of antibodies, type 2 cytokines, and regulatory signals after cure indicates that these markers track active infection rather than permanent immune reprogramming.

The clinical implications of this work are considerable. Serological diagnosis of strongyloidiasis already relies heavily on detecting parasite-specific antibodies, and the demonstration that IgG4 and IgG1 dominate the response supports the use of subclass-specific assays to improve sensitivity and specificity, particularly in endemic regions where cross-reactivity with other helminths complicates interpretation. Moreover, the finding that antibody levels and type 2 and type 9 cytokines fall measurably after successful treatment raises the possibility of using these immune markers as indicators of cure, something parasitological methods alone have struggled to provide given the intermittent shedding of larvae. In an era of increasing immunosuppressive therapy worldwide, reliable tools to verify parasite elimination before immunosuppression could save lives.

The study also contributes to a broader scientific conversation about how helminths modulate human immunity. Chronic worm infections are widely studied for their immunoregulatory effects, which some researchers hope to harness for treating autoimmune and inflammatory diseases. By documenting, in a well-characterized human cohort, the coordinated suppression of Th1 and Th17 pathways alongside a preserved interferon-inducible chemokine response, the Iranian-German team provides a nuanced dataset that moves beyond the simple dichotomy of type 1 versus type 2 immunity. It shows that natural infection produces a layered and partially contradictory immune landscape whose resolution after treatment can now be followed over time.

Limitations remain, as with any field study conducted in an endemic setting. The number of longitudinally followed patients was modest, and the six-month follow-up window, while sufficient to observe significant immune changes, leaves open questions about the long-term durability of antibody and cytokine normalization. The endemic controls, though carefully selected, cannot fully exclude prior exposure or unrecognized low-level infection. Nevertheless, the study stands as a substantial advance for a disease that has long been overshadowed by better-known tropical parasites. For the millions of people carrying S. stercoralis, many of them unaware of their infection, this work brings the prospect of sharper diagnostics, clearer markers of therapeutic success, and a deeper understanding of the delicate immune equilibrium that this remarkable parasite has evolved to maintain within its human host.

Subject of Research: Immune response profiling in Strongyloides stercoralis infection

Article Title: Systemic profiles of Strongyloides-specific IgG subclass, cytokine, and chemokine response in an eosinophilic Iranian population infected with Strongyloides stercoralis

Article References: Beiromvand, M., Ashiri, A., Rafiei, A., Heepmann, L., Hartmann, W., Linnemann, L., Tappe, D., Veit, A., & Breloer, M. (2026). Systemic profiles of Strongyloides-specific IgG subclass, cytokine, and chemokine response in an eosinophilic Iranian population infected with Strongyloides stercoralis. Parasites & Vectors. https://doi.org/10.1186/s13071-026-07683-9

Image Credits: AI Generated

DOI: 10.1186/s13071-026-07683-9

Keywords: Strongyloides stercoralis, strongyloidiasis, IgG subclasses, cytokines, chemokines, eosinophils, type 2 immunity, albendazole, immunomodulation, Iran, neglected tropical disease, parasitic infection

The burden of sleeping sickness is considerable. The disease progresses in stages, beginning with fever, headaches and lymphadenopathy as parasites multiply in the blood and lymph, and advancing to neurological involvement once the parasites cross the blood-brain barrier, producing sleep disturbances, cognitive decline and, if untreated, death. The parasite’s most formidable weapon is antigenic variation: a dense coat of variant surface glycoproteins, or VSGs, that is continually reshuffled through gene conversion, allowing the parasite to stay one step ahead of the host antibody response. This immune evasion strategy, well documented in the literature, has long frustrated conventional vaccine development, which is one reason the researchers turned to conserved, functionally essential proteins as alternative targets.

Specifically, the team selected three T. brucei proteins as the basis for their construct: the variant surface glycoprotein itself, heat shock protein 70, and the vacuolar transporter chaperone complex. Heat shock protein 70 is a highly conserved molecular chaperone central to protein folding and stress responses, while the vacuolar transporter chaperone complex is involved in polyphosphate synthesis and acidocalcisome function, processes essential to parasite survival. By mining these proteins for immunogenic peptides, the researchers aimed to build a construct that combines surface exposure with conservation across strains, increasing the likelihood that an immune response raised against the vaccine would recognize the parasite before it can establish infection.

The design workflow followed the now-standard logic of reverse vaccinology. Protein sequences were retrieved from the UniProt database and aligned with tools such as Clustal Omega to assess conservation. Cytotoxic T lymphocyte epitopes were predicted for MHC class I presentation, and helper T lymphocyte epitopes for MHC class II, using the Immune Epitope Database analysis resource and related servers. B-cell epitopes were predicted with linear and discontinuous methods, including ElliPro for structure-based antibody epitope mapping. Each candidate epitope was then filtered for allergenicity with AllerTOP, for toxicity with dedicated peptide toxicity predictors, and for antigenicity with VaxiJen, ensuring that only immunogenic, non-allergenic and non-toxic peptides entered the final construct.

Population coverage analysis, which estimates how many people worldwide carry HLA alleles capable of presenting the chosen epitopes, returned a striking result: the vaccine candidate achieved 100 percent global population coverage. This metric matters because a vaccine that only fits a narrow slice of HLA diversity would leave large populations unprotected. Biophysical characterization of the final multi-epitope protein showed an aliphatic index of 71.23, indicating good thermal stability, and a GRAVY score of minus 0.719, indicating a hydrophilic, soluble protein likely to fold and express well. Solubility and instability assessments supported the view that the construct should behave as a stable, expressible protein in a cellular context.

Structural modeling came next. The tertiary structure of the vaccine construct was predicted and evaluated with a TM-score of 0.65 plus or minus 0.13 and a C-score of minus 0.50, values consistent with a reliable fold. The model was then refined, and validation metrics confirmed its quality: a Ramachandran score of 86.8 percent, meaning the vast majority of residues occupy favored or allowed backbone conformations, and a ProSA Z-score of minus 5.26, within the range expected for proteins of comparable size. Disulfide engineering was considered to further stabilize the fold, and secondary structure predictions from PSIPRED and SOPMA were used to cross-check the modeled architecture.

To test whether the vaccine could actually engage the innate immune sensors that trigger adaptive responses, the team docked the construct against Toll-like receptors 2 and 4, key pattern-recognition receptors on antigen-presenting cells. Molecular docking predicted strong binding, with energy scores of minus 1013.5 kJ/mol for TLR-2 and minus 1002.8 kJ/mol for TLR-4. These docked complexes were then subjected to molecular dynamics simulation, principal component analysis, dynamic cross-correlation matrix analysis and MM-GBSA binding free energy calculations, all of which supported the stability and favorable energetics of the receptor-vaccine interactions. In practical terms, the simulations suggest the vaccine construct should bind robustly to the very receptors that initiate the innate immune cascade.

Immune simulation provided the most direct readout of the construct’s potential immunogenicity. Using computational immune system modeling, the researchers predicted robust humoral and cell-mediated responses, including elevated B lymphocyte and T lymphocyte populations and rising titers of IgM and IgG antibodies over the simulated immunization course. Cytokine profiles indicated activation of both Th1-type and Th2-type pathways, the dual signature generally desired in a prophylactic vaccine. While such simulations are approximations of a vastly more complex biological reality, they serve as a critical screening step, allowing weak candidates to be discarded before any laboratory resource is spent.

Because the platform is mRNA, the team also optimized the nucleic acid sequence itself. Codon optimization for expression in Escherichia coli strain K12, conducted for in-silico cloning into the pET-28a(+) vector, yielded a codon adaptation index of 0.9688 and a GC content of 44.70 percent, both indicative of high expression potential. In-silico cloning confirmed that the construct could be inserted into the vector without disrupting restriction sites. Finally, minimum free energy analysis of the mRNA sequence was used to evaluate the structural integrity and stability of the transcript, an important consideration since mRNA secondary structure influences translation efficiency and vaccine performance.

The authors are careful to frame the work as a computational proof of concept rather than a finished vaccine. As they conclude, the in-silico designed candidate demonstrated strong structural stability, favorable receptor interactions and promising immunogenic potential against T. brucei, but experimental validation and in-vivo studies are required to verify its safety and efficacy. That caveat applies to the entire field of computational vaccinology: docking scores and immune simulations can prioritize candidates and dramatically shorten development timelines, but only animal studies and clinical trials can establish whether a designed construct protects against real infection. Still, for a disease with no licensed vaccine, in which drug therapy is costly, logistically difficult and increasingly challenged by resistance, a rationally designed mRNA candidate that clears every computational hurdle represents a meaningful step forward, and a template for applying the same pipeline to other neglected tropical parasites.

Subject of Research: Computational immunoinformatics design of an mRNA vaccine candidate against the sleeping sickness parasite Trypanosoma brucei

Article Title: Immunoinformatics Approach for the Designing of a Novel mRNA Vaccine Candidate Against Trypanosoma brucei

Article References: Nil, M. S., Khandker, S., Sadaf, S., Ahmed, N., Reja, S., Sayfullah, M., Ferdous, J., Saha, S., Alamri, A., Khan, M. S., Ahmed, S., Wajed, S., Mahdeen, A. A., & Siddiquee, N. H. (2026). Immunoinformatics Approach for the Designing of a Novel mRNA Vaccine Candidate Against Trypanosoma brucei. Acta Parasitologica, 71(5), Article 205. https://doi.org/10.1007/s11686-026-01388-w

Image Credits: AI Generated

DOI: 10.1007/s11686-026-01388-w

Keywords: Trypanosoma brucei, human African trypanosomiasis, mRNA vaccine, immunoinformatics, reverse vaccinology, epitope prediction, molecular docking, molecular dynamics simulation, TLR-2, TLR-4, codon optimization, neglected tropical disease

Neurocysticercosis arises when larvae of the pork tapeworm Taenia solium lodge in the brain after a person swallows eggs shed by a human carrier, most often through contaminated food or water. Where the larvae settle determines how sick the patient becomes. When cysts embed in the brain parenchyma, they typically cause seizures and headaches, symptoms that usually respond to antiepileptic drugs, analgesics, and anthelmintic therapy, and the illness often follows a relatively benign course. When the parasites instead float freely within the cerebrospinal fluid compartments, the ventricles and the subarachnoid space, the picture changes dramatically. This extraparenchymal form responds poorly to anthelmintic drugs and can produce vasculitis, disrupted fluid circulation, and raised intracranial pressure driven by hydrocephalus. Basal subarachnoid disease is regarded as the most lethal presentation, carrying high rates of mortality and neurological disability.

The therapeutic dilemma at the heart of extraparenchymal disease is that treatment itself can make things worse. When cysts begin to degenerate, they ignite a marked inflammatory response inside the fluid compartments of the brain. Corticosteroids are routinely deployed to suppress this inflammation and prevent catastrophic complications, yet the same drugs may blunt the effectiveness of cysticidal agents, protecting the host but also sheltering the parasite. Clinical recommendations for managing these patients rest on studies with limited levels of evidence, which is precisely why researchers have long sought laboratory models that faithfully recapitulate the anatomy and immunology of the human infection.

Several experimental platforms exist, built on different parasites, including Taenia solium, Taenia crassiceps, and Mesocestoides corti, and different hosts, ranging from monkeys and pigs to rats and mice. A rat model developed by the Cysticercosis Working Group in Peru uses intracranial injection of activated T. solium oncospheres and has the advantage of employing the very species that causes human disease, but harvesting oncospheres from patients with taeniasis is not always feasible. The Brazilian team, led by Sophia Rossi de Barros Almeida and Pedro Tadao Hamamoto Filho of Botucatu Medical School at São Paulo State University, instead exploited a model in which 50 intact T. crassiceps cysticerci, each roughly half a millimetre in diameter, are suspended in saline and injected through a 25-gauge needle into the cisterna magna of six-week-old Wistar rats, mostly males, anesthetized with a ketamine and xylazine mixture.

To validate disease induction and chart the distribution of cysts throughout the cerebrospinal fluid compartments, the investigators examined magnetic resonance images acquired on a 0.25-T scanner with 0.6-millimetre slice thickness and T2-weighted gradient-echo acquisition, performed between one and six months after inoculation. Ventricular enlargement was quantified using the frontal horn ratio, a standard human neuroradiological measure calculated by dividing the maximal width of the frontal horns of the lateral ventricles by the inner-table-to-inner-table cranial diameter at the same level, with values above 0.3 indicating hydrocephalus. Because the low-field equipment could not resolve individual cysts, the team treated enlarged cisterns as indirect evidence of cyst presence, an assumption grounded in their empirical experience of imaging followed by euthanasia and necropsy.

The results were unambiguous. Intracranial abnormalities appeared in 189 of the 300 animals, or 63.0 percent, in the form of ventricular enlargement, subarachnoid space enlargement, or both. More than 90 percent of the animals with abnormalities showed ventricular dilation, predominantly of the lateral ventricles. The cisterna magna was the most frequently affected compartment at 85.2 percent, followed by the supratentorial basal cisterns at 78.8 percent, peritruncal cisterns anterior to the brainstem, the region near the pineal gland, the spinal canal, and, less commonly, the cerebral convexity, where abnormal spaces were seen in 10.6 percent of cases. Cysts were also detected outside the skull entirely, burrowing into the subcutaneous tissue of the neck in 39.2 percent of infected animals, a reminder of the parasite’s remarkable migratory capacity.

The frontal horn ratio ranged from 0.28 to 0.92, with a mean of 0.62 plus or minus 0.13, roughly double the human threshold for hydrocephalus and a striking severity given the animals’ mild clinical impairment. Notably, the presence of cysts in any cerebrospinal fluid compartment was associated with higher frontal horn ratios, whereas subcutaneous cyst location made no difference to ventricular size, with mean ratios of 0.622 versus 0.616 and a non-significant p-value of 0.743. Eleven animals, or 5.8 percent, were judged infected despite the absence of ventricular enlargement; in these, cysts clustered in the subcutaneous tissue and the cisterna magna. Subcutaneous cysts were found in 39.2 percent of intracranially infected animals and 30.2 percent of noninfected animals, with no statistically significant difference between the groups, suggesting skin involvement alone does not predict brain disease.

The parallels with human imaging are what give the model its translational punch. In a clinical study cited by the authors, 86.1 percent of patients with extraparenchymal neurocysticercosis harbored cysts in the posterior fossa cisterns, figures that correspond almost exactly to the 85.2 percent cisterna magna involvement and 57.1 percent peritruncal involvement seen in the rats, an expected overlap given that cysts are injected directly into that compartment. More intriguingly, cysts were also identified within the ventricles and supratentorial cisterns of the animals, demonstrating that the parasites can migrate across different fluid compartments just as they do in humans. The model even reproduces spinal disease, an uncommon but feared manifestation of human cysticercosis in which subarachnoid cysts cause motor deficits, back pain, and hydrocephalus, offering a potential platform for studying spinal cord compression.

Mechanistically, the model captures both routes by which hydrocephalus develops in human disease. Direct injection of cysts into the subarachnoid space obstructs the outflow of cerebrospinal fluid from the fourth ventricle, while inflammation along the ependymal lining adds an additional block to absorption. Yet the inflammatory response in infected animals appears attenuated, probably through the action of regulatory T cells, mirroring the immune evasion that allows cysts to survive for years in patients. Only after anthelmintic treatment, and particularly in the absence of corticosteroid cover, does inflammation intensify, reproducing the clinical paradox in which therapy for humans can worsen hydrocephalus and intracranial hypertension. Earlier work from the same group showed that T. crassiceps cysts injected into the subarachnoid space of rats simulate the radiological and morphological features of racemose neurocysticercosis, the multiloculated, grape-like form of the disease.

The authors acknowledge the inherent limitation of using a parasite species that differs from the one responsible for human illness, since species-specific host responses may not be fully reproduced, and they concede that their low-field open MRI system could neither count cysts nor reliably distinguish enlarged cisterns from cyst presence, a distinction that in humans does not always correspond either. Even so, their findings are comparable to those obtained with a 7-Tesla scanner in an adapted version of the model, and the higher parasite burden used here, 50 versus 30 cysts, may explain the greater disease severity, particularly the pronounced hydrocephalus. Taken together, the neuroimaging evidence cements this rat model as a practical, reproducible, and ethically sustainable platform for preclinical testing of new anti-inflammatory schedules, optimized anthelmintic regimens, surgical adjuncts, and even vaccines, against a neglected but potentially eradicable disease that still burdens millions across Latin America, Asia, and Africa.

Subject of Research: Neuroimaging features of an experimental rat model of extraparenchymal neurocysticercosis

Article Title: Neuroimaging Features of an Experimental Model of Extraparenchymal Neurocysticercosis

Article References: Almeida, S. R. D. B., Martins, T. D. C., Caldeira, F. M. C., Machado, V. M. D. V., Zanini, M. A., & Hamamoto Filho, P. T. (2026). Neuroimaging Features of an Experimental Model of Extraparenchymal Neurocysticercosis. Acta Parasitologica, 71(5), Article 200. https://doi.org/10.1007/s11686-026-01393-z

Image Credits: AI Generated

DOI: 10.1007/s11686-026-01393-z

Keywords: neurocysticercosis, Taenia crassiceps, hydrocephalus, MRI, experimental model, cerebrospinal fluid, frontal horn ratio, subarachnoid space, cisterna magna, Wistar rats, parasitic infection, neglected tropical disease